Comprehensive molecular characterization of infant medulloblastoma has uncovered the high degree of heterogeneity of this disease. Recent results from the SJYC07 study elegantly reveal that risk stratification can be improved if DNA methylation profiling data are incorporated into clinicopathological criteria. Importantly, the delineation of disease subgroups potentially has major clinical implications.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rutkowski, S. et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J. Clin. Oncol. 28, 4961–4968 (2010).
Ramaswamy, V. et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 131, 821–831 (2016).
Taylor, M. D. et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123, 465–472 (2012).
Robinson, G. W. et al. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol. 19, 768–784 (2018).
Rutkowski, S. et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N. Engl. J. Med. 352, 978–986 (2005).
Lafay-Cousin, L. et al. Clinical, pathological, and molecular characterization of infant medulloblastomas treated with sequential high-dose chemotherapy. Pediatr. Blood Cancer 63, 1527–1534 (2016).
Rutkowski, S. et al. Medulloblastoma in young children. Pediatr. Blood Cancer 54, 635–637 (2010).
Capper, D. et al. DNA methylation-based classification of central nervous system tumors. Nature 555, 469–474 (2018).
Cavalli, F. M. G. et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31, 737–754 (2017).
Ramaswamy, V. et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 14, 1200–1207 (2013).
Acknowledgements
M.R. acknowledges support from the Pediatric Brain Tumor Foundation. V.R. acknowledges support from the American Brain Tumor Association and the Brain Tumour Foundation of Canada.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Remke, M., Ramaswamy, V. Infant medulloblastoma — learning new lessons from old strata. Nat Rev Clin Oncol 15, 659–660 (2018). https://doi.org/10.1038/s41571-018-0071-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0071-6
This article is cited by
-
Medulloblastoma: “Onset of the molecular era”
Molecular Biology Reports (2020)
